ClinicalTrials.gg
Not yet recruitingNCT07345624Updated Jan 16, 2026

Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B

A Phase 4 interventional study of Entecavir and Entecavir + Pegylated interferon α-2b in Hepatitis B Virus Infection, Children and Chronic Hepatitis B, sponsored by Qing-Lei Zeng. Not yet recruiting. Open to participants aged 3 Years to 6 Years. Per ClinicalTrials.gov, last updated 2026-01-16.

Primary conditionHepatitis B, ChronicRegistry: Hepatitis BReclassifiedWhy we changed it
Registry
Hepatitis B — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis B, Chronic
Why
  1. The study's listed conditions name Hepatitis B, Chronic, a narrower term within Hepatitis B.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Qing-Lei Zeng · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
3 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.

Planned enrollment
37th of 61
80 · median 109
Started
2026
with 2 others
Phase 4
33 of 64
2 open now
Registered
63rd of 64
by date
Lead sponsor
2 of 64
Qing-Lei Zeng

Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 37th largest by planned enrollment of the 61 interventional ones that give a count, is one of 3 that started in 2026, is one of 33 in phase 4, and was the 63rd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 3 Years to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing entecavir in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-tolerant, HBeAg-positive children aged 3-6 years with chronic hepatitis B virus infection.

Read the detailed description

This is a multicenter, open-label, randomized controlled, phase 4 trial enrolling 3-6-year-old children with immune-tolerant HBeAg-positive chronic HBV infection. Participants will be randomly assigned in a 1:1 ratio to two treatment arms, both lasting 96 weeks. The ETV group will receive entecavir (ETV) monotherapy throughout the 96-week treatment course (ETV group). The pegylated interferon (Peg-IFN) group will receive ETV for the first 48 weeks, followed by combination therapy with Peg-IFN α-2b for the remaining 48 weeks (ETV plus IFN combination group). The primary endpoint is the functional cure rate at 24 weeks after treatment discontinuation (week 120). The main secondary endpoints include the rates of undetectable HBV DNA, HBeAg loss, and HBsAg loss at week 24, 48, 72, 96, and 120, and rates of alanine aminotransferase elevation or flares (>5 times of upper limit of normal) and incidence of adverse events at any time during the study. The study will also explore associations between functional cure and baseline or on-treatment parameters. A total of 80 children (40 per group) is required to detect a statistically significant difference between two treatment arms.

03

Conditions studied

  • Hepatitis B Virus Infection
  • Children
  • Chronic Hepatitis B

Browse trials for

Keywords

  • Children
  • Efficacy
  • Safety
  • Chronic
  • Pegylated interferon α-2b
  • Hepatitis B virus
  • Entecavir
  • Functional cure
  • Immune-tolerant
04

In context

Hepatitis B, Chronic Reclassified

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

This study's planned enrollment of 80 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.

Browse Hepatitis B, Chronic studies →

Lead sponsor

Qing-Lei Zeng is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
3 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 3-6 (more than 3 but less than 7) years;
  2. With chronic infection;
  3. HBeAg-positive;
  4. HBV DNA >1.0×10⁷ IU/mL;
  5. Normal upper abdominal ultrasound;
  6. \<40 U/L, HBsAg positivity, HBeAg positivity, and HBV DNA>1.0×10⁷IU/mL for at least two times, with an interval of 6 months or more.

Exclusion criteria

Exclusion Criteria:

  1. Previous antiviral treatment for chronic infection;
  2. Coinfection with , D, E, (HIV), Epstein-Barr virus, or cytomegalovirus;
  3. Previous or current evidence of hepatocellular carcinoma or cirrhosis;
  4. Coexistence of any other liver diseases such as hepatitis, drug-induced liver injury or Wilson's disease;
  5. Coexistence of systemic/other organ disorders (for example with evidence of thyroid disorders);
  6. level \<100 g/L.
  7. \<1.0×10⁹/L;
  8. count \<125×10⁹/L;
  9. Total >1 , i.e., 17.1 μmol/L;
  10. Albumin level \<35 g/L;
  11. Concurrent treatment with other drugs, including but not limited to nephrotoxic drugs, immune modulators, cytotoxic drugs, Chinese traditional medicine or supplements, nonsteroidal anti-inflammatory drugs, or .
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Entecavir

    Receive entecavir monotherapy throughout the 96-week treatment course.

    Drug: Entecavir

  • Experimental
    Entecavir plus Peg-IFN α-2b

    Receive entecavir for the first 48 weeks, followed by combination therapy with pegylated interferon α-2b for the remaining 48 weeks.

    Drug: Entecavir + Pegylated interferon α-2b

Interventions

  • Receive entecavir onotherapy throughout the 96-week treatment course, the dosage of entecavir is 0.015 mg/kg/day for those weighing between 10 and 30 kg; for those weighing more than 30 kg, the dosage is 0.5 mg/day, oral.

    Also known as: Runzhong®

  • DrugEntecavir + Pegylated interferon α-2b

    Drug page: Entecavir

    Receive entecavir (with dosing adjusted by body weight: 0.015 mg/kg/day for subjects weighing 10-30 kg, and 0.5 mg/day for those \>30 kg, oral) for the first 48 weeks, followed by combination therapy with pegylated interferon α-2b (104 μg/m², weekly, subcutaneous injection) for the remaining 48 weeks.

    Also known as: Runzhong®, PEGBING®

07

What researchers measure

Primary outcomes

  1. The rate of functional cure

    Functional cure is defined as the loss of HBsAg to \<0.05 IU/mL and HBeAg clearance, with or without the presence of hepatitis B surface antibody (HBsAb) and hepatitis B e antibody (HBeAb), and undetectable HBV DNA (\<10 IU/mL) at the end of treatment, sustained through 24 weeks post-treatment.

    Time frame: At 24 weeks after treatment cessation.

Secondary outcomes

  1. The rate of HBV DNA undetectable

    Proportion of participants with HBV DNA undetectable, defined as HBV DNA \<10 IU/mL.

    Time frame: At week 24, 48, 72, 96, 120 of the study.

  2. The rate of HBeAg loss

    Proportion of participants with HBeAg loss, defined as HBeAg \<0.18 PEIU/mL.

    Time frame: At week 24, 48, 72, 96, 120 of the study.

  3. The rate of HBsAg loss

    Proportion of participants with HBsAg loss, defined as HBsAg \<0.05 IU/mL.

    Time frame: At week 24, 48, 72, 96, 120 of the study.

  4. The rate of alanine aminotransferase elevation or flare

    Proportion of participants with alanine aminotransferase elevation (\> 1 time the upper limit of normal, i.e., \>40 U/L) or flare rate, defined as ALT \>5 times the upper limit of normal, i.e., \>200 U/L.

    Time frame: At any time during the study, i.e., from the date of patient enrollment through 24 weeks after treatment discontinuation.

  5. The rate of cytopenia rate

    Proportion of participants with cytopenia, defined as an absolute neutrophil count \<1.0×10⁹/L and/or a platelet count \<100×10⁹/L.

    Time frame: At any time during the study, i.e., from the date of patient enrollment through 24 weeks after treatment discontinuation.

  6. The rate of growth suppression

    Growth suppression rate, defined as height and weight measurements falling below expected levels based on Chinese national standards and World Health Organization anthropometric z-scores for child growth.

    Time frame: At week 24, 48, 60, 72, 84, 96, 108, 120 of the study.

  7. The rate of thyroid dysfunction

    Proportion of participants with thyroid dysfunction rate, defined as thyroid-stimulating hormone (TSH, normal range 0.27-10 mU/L), free thyroxine (FT4, normal range 10.3-31 pmol/L), or free triiodothyronine (FT3, normal range 3-11.4 pmol/L) levels exceeds the limit of normal or the lower limit of normal .

    Time frame: At week 72, 96, and 120 of the study.

  8. Any other adverse event

    Incidence of other adverse event at any time during study, including but not limited to flu-like symptoms and signs, rash, and other expected or unexpected adverse event.

    Time frame: At any time during study, i.e., from the date of patient enrollment through 24 weeks after treatment discontinuation.

08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2030, 59 months later.

Of 46 non-industry phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 83. This study's planned 59 months is above that.

Counting every sponsor, half of 63 studies reached it within 44 months; a quarter within 30 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2025
First posted
Jan 16, 2026
StartEst.
Jan 11, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07345624
Lead sponsor
Qing-Lei Zeng
Collaborators
Henan Provincial People's Hospital, Luoyang Central Hospital, Xuchang Central Hospital, Luohe Central Hospital, Yongcheng People's Hospital, Sanmenxia Central Hospital, The Third Affiliated Hospital of Henan Medical University, Weishi County People's Hospital, The Sixth People's Hospital of Zhengzhou, The First Affiliated Hospital of Zhengzhou University, Shangcheng County People's Hospital, The First Affiliated Hospital of Henan Polytechnic University, Nanyang Central Hospital
Responsible party
Qing-Lei Zeng (Professor, The First Affiliated Hospital of Zhengzhou University) — Sponsor-investigator
First posted
Jan 16, 2026
Start date
Jan 11, 2026 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jan 16, 2026

Study contacts

Qing-Lei Zeng, M.D.
Contact
zengqinglei2009@163.com
86 15838120512
Zu-Jiang Yu, M.D.
Contact
johnyuem@zzu.cn
86 186 0371 0022
Qing-Lei Zeng, M.D.
principal investigator · The First Affiliated Hospital of Zhengzhou University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion